Editorial

Laboratory of Pharmacology, Medical School, Democritus University of Thrace, Alexandroupolis, 68100, Greece

Individualised Medicine & Pharmacological Research Solutions Center (IMPReS), Alexandroupolis, 68100, Greece

Search for more papers by this author

Vangelis G Manolopoulos

*Author for correspondence: Tel.: +30 2551 030 523;

E-mail Address: emanolop@med.duth.gr

https://orcid.org/0000-0003-0849-5469

Laboratory of Pharmacology, Medical School, Democritus University of Thrace, Alexandroupolis, 68100, Greece

Individualised Medicine & Pharmacological Research Solutions Center (IMPReS), Alexandroupolis, 68100, Greece

Clinical Pharmacology Unit, Academic General Hospital of Alexandroupolis, Alexandroupolis, 68100, Greece

Search for more papers by this author

Published Online:26 Oct 2022https://doi.org/10.2217/pgs-2022-0145

View article

Abstract

Tweetable abstract

The pharmaco-omics revolution has started and, as a wild stream, sooner or later, will expand and dramatically improve drug discovery and individual response to pharmacotherapy. Hopefully, we will all be ready to follow the stream.

Keywords:

References

1. Manolopoulos VG, Dechairo B, Huriez A et al. Pharmacogenomics and personalized medicine in clinical practice. Pharmacogenomics 12(5), 597–610 (2011).
Google Scholar
2. Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenetics of coumarinic oral anticoagulants. Pharmacogenomics 11(4), 493–496 (2010).
CASGoogle Scholar
3. Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. Pharmacogenomics 12(8), 1161–1191 (2011).
CASGoogle Scholar
4. Ragia G, Dahl ML, Manolopoulos VG. Influence of CYP3A5 polymorphism on the pharmacokinetics of psychiatric drugs. Curr. Drug Metab. 17(3), 227–236 (2016).
Medline CASGoogle Scholar
5. Ragia G, Manolopoulos VG. Personalized medicine of alcohol addiction: pharmacogenomics and beyond. Curr. Pharm. Biotechnol. 18(3), 221–230 (2017).
Medline CASGoogle Scholar
6. Ragia G, Manolopoulos VG. From Homer and Hippocrates to modern personalized medicine: is there a role for pharmacoepigenomics in the treatment of alcohol addiction? Pharmacogenomics 19(6), 513–516 (2018).
CASGoogle Scholar
7. Nepali K, Liou JP. Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends. J. Biomed. Sci. 28(1), 27 (2021).
Medline CASGoogle Scholar
8. Feng J, Meng X. Histone modification and histone modification-targeted anti-cancer drugs in breast cancer: fundamentals and beyond. Front. Pharmacol. 13, 946811 (2022).
Medline CASGoogle Scholar
9. Tang F, Lao K, Surani MA. Development and applications of single-cell transcriptome analysis. Nat. Methods 8(Suppl. 4), S6–S11 (2011).
Medline CASGoogle Scholar
10. Xicota L, De Toma I, Maffioletti E et al. Recommendations for pharmacotranscriptomic profiling of drug response in CNS disorders. Eur. Neuropsychopharmacol. 54, 41–53 (2022).
Medline CASGoogle Scholar
11. Graves PR, Haystead TA. Molecular biologist’s guide to proteomics. Microbiol. Mol. Biol. Rev. 66(1), 39–63 (2002).
Medline CASGoogle Scholar
12. Chapal N, Molina L, Molina F, Laplanche M, Pau B, Petit P. Pharmacoproteomic approach to the study of drug mode of action, toxicity, and resistance: applications in diabetes and cancer. Fundam. Clin. Pharmacol. 18(4), 413–422 (2004).
Medline CASGoogle Scholar
13. Li S, Yang Z, Yao M et al. Exploration for biomarkers of postpartum depression based on metabolomics: a systematic review. J. Affect. Disord. 317, 298–306 (2022).
Medline CASGoogle Scholar
14. Hassan M, Awan FM. Innovations in genomics and big data analytics for personalized medicine and health care: a review. Int. J. Mol. Sci. 23(9), 4645 (2022).
Medline CASGoogle Scholar
15. Morello G, Salomone S, D'agata V, Conforti FL, Cavallaro S. From multi-omics approaches to precision medicine in amyotrophic lateral sclerosis. Front. Neurosci. 14, 577755 (2020).
MedlineGoogle Scholar
16. Hu C, Jia W. Multi-omics profiling: the way towards precision medicine in metabolic diseases. J. Mol. Cell Biol. 13(8), 576–593 (2021).
CASGoogle Scholar
17. Banerjee S, Prabhu Basrur N, Rai PS. Omics technologies in personalized combination therapy for cardiovascular diseases: challenges and opportunities. Per. Med. 18(6), 595–611 (2021).
CASGoogle Scholar
18. Valenti F, Falcone I. Precision medicine and melanoma: multi-omics approaches to monitoring the immunotherapy response. Int. J. Mol. Sci. 22(8), 3837 (2021).
Medline CASGoogle Scholar
19. Chakraborty S, Hosen MI. Onco-multi-OMICS approach: a new frontier in cancer research. BioMed Res. Int. 2018, 9836256 (2018).
MedlineGoogle Scholar
20. Olivier M, Asmis R. The need for multi-omics biomarker signatures in precision medicine. Int. J. Mol. Sci. 20(19), 4781 (2019).
Medline CASGoogle Scholar

Vol. 23, No. 16

Metrics

Downloaded 84 times

History

Received 5 October 2022

Accepted 6 October 2022

Published online 26 October 2022

Published in print November 2022

Information

Keywords

Financial & competing interests disclosure

Financial support for project IMPReS (MIS 5047189) to V Manolopoulos was provided by the Program ‘Competitiveness, Entrepreneurship and Innovation’ (NSRF 2014–2020) co-sponsored by Greece and the European Union (European Regional Development Fund). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download

The revolution of pharmaco-omics: ready to open new avenues in materializing precision medicine?

Abstract

Tweetable abstract

References